Bupa's Emily Amos on the need for 'bold' reform

March 8, 2021 Other Health

This is a preview of subscriber content

Subscribe now to continue reading.

Emily Amos, the managing director of Bupa Health Insurance, says premiums will continue to rise because the cost of health care is increasingly driven by the ageing of the population, medical advances but also inefficiencies and waste. …

Subscribe now to continue reading.

Latest Video

We asked ChatGPT to produce a podcast script explaining the pros and cons of the HTA Review
August 10, 2025 - Latest News
Could the realities of AI quickly date or even swamp the HTA Review outcomes?
August 11, 2025 - Latest News
If the cost of this process is truly rising at this rate, then the process must be the problem
August 12, 2025 - Latest News
Biogen announces leadership transition for Australia and New Zealand
August 12, 2025 - Latest News
Pharmac announces plan to update access and supply of COVID-19 treatments
August 12, 2025 - Latest News

Bupa's Emily Amos on the need for 'bold' reform

This is a preview of subscriber content

Latest Video

Most Read

We asked ChatGPT to produce a podcast script explaining the pros and cons of the HTA Review

Could the realities of AI quickly date or even swamp the HTA Review outcomes?

If the cost of this process is truly rising at this rate, then the process must be the problem

Biogen announces leadership transition for Australia and New Zealand

Pharmac announces plan to update access and supply of COVID-19 treatments

New Stories

Experienced innovation leader joins AusBiotech as its Head of Investment

Government review and action timelines are in 'dog years' compared to AI

Australia is not alone in tripping over reform of medical device funding frameworks

Biogen announces leadership transition for Australia and New Zealand

If the cost of this process is truly rising at this rate, then the process must be the problem

Pharmac announces plan to update access and supply of COVID-19 treatments

Syntara receives FDA guidance for amsulostat in myelofibrosis treatment

Sign In

Bupa's Emily Amos on the need for 'bold' reform

This is a preview of subscriber content

Latest Video

Most Read

We asked ChatGPT to produce a podcast script explaining the pros and cons of the HTA Review

Could the realities of AI quickly date or even swamp the HTA Review outcomes?

If the cost of this process is truly rising at this rate, then the process must be the problem

Biogen announces leadership transition for Australia and New Zealand

Pharmac announces plan to update access and supply of COVID-19 treatments

Follow Us

New Stories

Experienced innovation leader joins AusBiotech as its Head of Investment

Government review and action timelines are in 'dog years' compared to AI

Australia is not alone in tripping over reform of medical device funding frameworks

Biogen announces leadership transition for Australia and New Zealand

If the cost of this process is truly rising at this rate, then the process must be the problem

Pharmac announces plan to update access and supply of COVID-19 treatments

Syntara receives FDA guidance for amsulostat in myelofibrosis treatment